ABBV Q4 2025 Earnings Analysis
Listen On
Available In
Key Highlights
- Revenue and earnings analysis for Q4 2025
- Key financial metrics and performance indicators
- Management guidance and outlook commentary
- Market position and competitive analysis
- AI-generated insights and analysis
Transcript
// Full episode scriptBeta Finch Podcast Script: AbbVie Q4 2025 Earnings
Welcome to Beta Finch, your AI-powered earnings breakdown where we digest the latest corporate earnings so you don't have to. I'm Alex.
And I'm Jordan. Today we're diving into AbbVie's fourth quarter 2025 results, and wow, what a story this pharmaceutical giant has to tell.
Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
Absolutely. Now Alex, AbbVie just delivered what CEO Robert Michael called "another excellent year," and the numbers certainly back that up. Let's start with the headline figures.
The numbers are pretty impressive, Jordan. AbbVie hit $61.2 billion in adjusted net revenues for the full year - that's a record high and beat their initial guidance by over $2 billion. They're looking at 8.6% sales growth despite facing nearly $16 billion in HUMIRA erosion since it lost exclusivity.
That HUMIRA erosion is the elephant in the room, isn't it? But what's fascinating is how they've more than offset those losses. Their adjusted earnings per share came in at $10 - that's 54 cents above their initial guidance midpoint. It really shows the power of their newer drugs.
Exactly, and speaking of those newer drugs, let's talk about the real stars of the show - SKYRIZI and RINVOQ. These two immunology powerhouses are absolutely crushing it.
The numbers are staggering. Combined, SKYRIZI and RINVOQ delivered about $25.9 billion in revenue - that's an $8 billion increase year-over-year. SKYRIZI alone hit $5 billion in the quarter with 31.9% operational growth, while RINVOQ came in at nearly $2.4 billion with 28.6% growth.
And here's what caught my attention - they're already exceeding their 2027 long-term guidance by half a billion dollars. For 2026, they're projecting combined sales of over $31 billion for these two drugs. That's remarkable momentum.
What's really interesting is how they're dominating in specific markets. In psoriasis, SKYRIZI has over 45% prescription share in the U.S. biologic market, and their capture rates for new patients are exceeding 55% - that's four times higher than their next closest competitor.
The competitive dynamics in IBD are particularly noteworthy. Despite new competition, SKYRIZI maintains a 75% capture rate in frontline IBD treatment, and it's even higher - 80% - specifically in Crohn's disease.
Now let's talk about what's really exciting for the future - their neuroscience portfolio. This segment delivered over $10.7 billion in revenue with nearly $1.8 billion in growth. But the real story here is Vialev, their Parkinson's treatment.
Vialev hit $183 million in the quarter - up 33% sequentially - and management is now projecting it'll reach blockbuster status in 2026. That's a billion-dollar drug in its early launch phase. Pretty remarkable.
And they're not stopping there. They see their entire Parkinson's franchise, including Vialev, Duopa, and the upcoming Tavapadon, potentially reaching $5 billion in peak sales. Add their migraine franchise, which they also expect to exceed $5 billion, and you're talking about some serious long-term growth drivers.
Let's shift to their pipeline because that's where AbbVie is really investing for the future. They spent nearly $1 billion more on R&D in 2025, fully funding 90 clinical programs. They also invested over $5 billion in business development.
Some of those acquisitions are fascinating - they picked up an in-vivo CAR-T platform, next-generation psychedelics for depression, a long-acting amylin analog for obesity, and even a novel siRNA platform. They're clearly positioning for the next decade of growth.
Speaking of positioning, there was an interesting political development. AbbVie signed a voluntary agreement with the U.S. government that commits them to $100 billion in U.S. R&D and capital investments over the next decade, while also getting exemptions from tariffs and certain pricing mandates.
That's a smart strategic move. It shows they're thinking long-term about maintaining their innovation edge while managing political risks. Now, let's talk guidance because that's what investors really want to know.
For 2026, AbbVie is projecting total sales growth of 9.5% to about $67 billion. Adjusted earnings per share guidance is between $14.37 and $14.57. Those are solid numbers, especially considering they're still facing HUMIRA headwinds and some pricing pressure on IMBRUVICA.
What struck me from the Q&A was management's confidence about long-term upside. CEO Michael specifically mentioned that street models aren't capturing the full potential of their neuroscience and oncology portfolios. He sees multiple $5 billion franchises emerging.
The oncology pipeline is particularly intriguing. Their ADC tmAbA is showing promising results across colorectal, lung, and other cancers. In colorectal cancer alone, they think it could be a multi-billion-dollar opportunity.
One thing that came up repeatedly was pricing pressure. They're expecting low single-digit pricing headwinds for SKYRIZI and RINVOQ going forward, which is pretty manageable given their volume growth.
The aesthetics business remains a challenge though. Botox Cosmetic and Juvederm are facing economic headwinds, and interestingly, Botox Therapeutic was selected for Medicare price negotiations in 2028, which was disappointing for management.
But they seem well-positioned overall. With no significant patent cliffs until the next decade and strong cash flow generation - they're projecting $18.5 billion in free cash flow for 2026 - they have plenty of firepower for more acquisitions and dividend growth.
What's your takeaway for investors, Jordan?
This feels like a company successfully navigating a major transition. Yes, they lost their biggest drug in HUMIRA, but they've built a diversified portfolio that's already more than replacing those revenues. The immunology franchise is dominant, neuroscience is emerging as a major growth driver, and they're investing heavily in future innovation.
I agree. The execution has been impressive, and the long-term outlook seems strong. They're not just managing decline - they're building for the next decade of growth across multiple therapeutic areas.
Before we wrap up, I need to remind everyone that everything we've discussed today is AI-generated analysis for educational purposes. Past performance doesn't guarantee future results. Please do your own due diligence.
That's right. AbbVie's story is compelling, but every investment carries risks. Thanks for joining us on Beta Finch. We'll be back next time with more AI-powered earnings analysis.
Until then, keep learning and stay curious about the markets! ---